Progression-Free Survival by Independent Review Committee (IRC)1

Kaplan-Meier Curve

Primary endpoint met demonstrating non-inferior IRC-assessed progression-free survival between acalabrutinib and ibrutinib1

IRC-assessed PFS1

IRC-assessed PFS1

Note: Median follow-up: 40.9 months (range, 0.0–59.1)

Forest Plot

IRC-assessed progression-free survival similar across prespecified subgroups2

IRC-assessed PFS across prespecified subgroups2

IRC-assessed PFS across prespecified subgroups2

aPer interactive voice-web response system record

Abbreviations

CI = confidence interval

;

ECOG = Eastern Cooperative Oncology Group 

;

IGHV = immunoglobulin heavy-chain variable gene

;

IRC = independent review committee 

;

PFS = progression-free survival 

;

TP53 = tumor protein p53

References

1. Byrd JC, Hillmen P, Ghia P, et al. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic lymphoma [oral presentation]. Presented at: American Society of Clinical Oncology (ASCO) Virtual Annual Meeting; June 4-8, 2021. Chicago, IL. Abstract 7500.
2. Byrd JC, Hillmen P, Ghia P, et al.  Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: Results of the first randomized Phase III trial. J. Clin. Oncol. 2021. https://doi.org/10.1200/JCO.21.01210.

Disclaimers

Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy. 

Document ID: b5f1a3c0-28eb-4186-8709-e3ddba7b6695
Last updated: 17-April-2023

©2023 AstraZeneca. All rights reserved.